CSTL Castle Biosciences, Inc.
Healthcare$20.15-1.90%ClosedMarket Cap: $611.1M
As of 2026-05-25
Valuation
P/E (TTM)
—
PEG
—
P/B
1.31
P/S
1.80
EV/EBITDA
-121.98
DCF Value
$-183.45
FCF Yield
0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
77.1%
Operating Margin
-9.8%
Net Margin
-3.8%
ROE
-2.8%
ROA
-2.3%
ROIC
-4.8%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $83.7M | 72.2% | $-18.4M | $-14.5M | $— | — |
| Q4 null | $87.0M | 79.0% | $-3.8M | $-2.3M | $— | — |
| FY null | $344.2M | 79.4% | $-42.8M | $-24.2M | $— | — |
| Q3 null | $83.0M | 77.5% | $-6.8M | $-501.0K | $— | — |
| Q2 null | $86.2M | 79.5% | $-4.3M | $4.5M | $— | — |
| Q1 null | $88.0M | 81.4% | $-27.9M | $-25.8M | $— | — |
| Q4 null | $86.3M | 81.3% | $4.0M | $9.6M | $— | — |
| FY null | $332.1M | 81.9% | $8.7M | $18.2M | $— | — |
| Q3 null | $85.8M | 81.8% | $5.1M | $2.3M | $— | — |
| Q2 null | $87.0M | 83.3% | $5.0M | $8.9M | $— | — |
| Q1 null | $73.0M | 81.0% | $-5.5M | $-2.5M | $— | — |
| Q4 2023 | $66.1M | 81.2% | $-5.7M | $-2.6M | $-0.10 | — |